Mesenchymal stem cell based exosome therapy (Cellular Biomedicine Group)(Mesenchymal stem cell based exosome therapy (Cellular Biomedicine Group))

概要

基本信息

药物类型

间充质干细胞疗法

别名

MSCsExos (Cellular Biomedicine Group)、hMSCExos (Cellular Biomedicine Group)

靶点-

作用机制-

治疗领域

呼吸系统疾病

在研适应症

急性呼吸窘迫综合征

非在研适应症

阿尔茨海默症成人呼吸窘迫综合征

原研机构

AbelZeta Pharma, Inc.

在研机构

AbelZeta Pharma, Inc.

非在研机构

上海交通大学医学院附属瑞金医院

上海赛比曼生物科技有限公司

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)临床1/2期

特殊审评-

登录后查看时间轴

关联

5

项与 Mesenchymal stem cell based exosome therapy (Cellular Biomedicine Group) 相关的临床试验

NCT04602104 / Completed临床1/2期IIT

A Multiple, Randomized, Double-blinded, Controlled Clinical Study of Allogeneic Human Mesenchymal Stem Cell Exosomes (hMSC-Exos) Nebulized Inhalation in the Treatment of Acute Respiratory Distress Syndrome

To evaluate allogeneic human mesenchymal stem cell exosomes (hMSC-Exos) in the treatment of acute respiratory distress syndrome (ARDS)

开始日期2020-11-30

申办/合作机构

上海交通大学医学院附属瑞金医院

[+1]

NCT04544215 / Suspended临床1/2期IIT

A Clinical Study of Allogeneic Human Adipose-derived Mesenchymal Progenitor Cell Exosomes (haMPC-Exos) Nebulizer for the Treatment of Carbapenem-resistant Gram-negative Bacilli-induced Pulmonary Infection

Evaluate the efficacy and safety of haMPC-Exos treatment with pulmonary infection caused by gram-negative bacilli resistant to carbapenems.

开始日期2020-07-01

申办/合作机构

上海交通大学医学院附属瑞金医院

[+1]

NCT04388982 / Unknown status临床1/2期IIT

Open-Label, Single-Center, Phase I/Ⅱ Clinical Trial to Evaluate the Safety and the Efficacy of Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in Patients With Mild to Moderate Dementia Due to Alzheimer's Disease

Evaluate the Safety and Efficacy of Exosomes Derived from Allogenic Adipose Mesenchymal Stem Cells（MSCs-Exos）in Subjects with Alzheimer's disease.

开始日期2020-07-01

申办/合作机构

上海交通大学医学院附属瑞金医院

[+1]

100 项与 Mesenchymal stem cell based exosome therapy (Cellular Biomedicine Group) 相关的临床结果

登录后查看更多信息

100 项与 Mesenchymal stem cell based exosome therapy (Cellular Biomedicine Group) 相关的转化医学

登录后查看更多信息

100 项与 Mesenchymal stem cell based exosome therapy (Cellular Biomedicine Group) 相关的专利（医药）

登录后查看更多信息

7

项与 Mesenchymal stem cell based exosome therapy (Cellular Biomedicine Group) 相关的文献（医药）

2024-08-01·Tissue Engineering and Regenerative Medicine

Desktop-Stereolithography 3D Printing of a Decellularized Extracellular Matrix/Mesenchymal Stem Cell Exosome Bioink for Vaginal Reconstruction

Article

作者: Zhang, Jingkun ; Li, Zhongkang ; Dong, Xiaoli ; Du, Yanfang ; Xiao, Yanlai ; Shi, Wenxin ; Huang, Xianghua ; Li, Qian ; Zheng, Jiahua

BACKGROUND3D-printing is widely used in regenerative medicine and is expected to achieve vaginal morphological restoration and true functional reconstruction. Mesenchymal stem cells-derived exosomes (MSCs-Exos) were applyed in the regeneration of various tissues. The current study aimed to explore the effctive of MSCs-Exos in vaginal reconstruction.METHODSIn this work, hydrogel was designed using decellularized extracellular matrix (dECM) and gelatin methacrylate (GelMA) and silk fibroin (SF). The biological scaffolds were constructed using desktop-stereolithography. The physicochemical properties of the hydrogels were evaluated; Some experiments have been conducted to evaluate exosomes' effect of promotion vaginal reconstruction and to explore the mechanism in this process.RESULTSIt was observed that the sustained release property of exosomes in the hydrogel both in vitro and in vitro.The results revealed that 3D scaffold encapsulating exosomes expressed significant effects on the vascularization and musule regeneration of the regenerative vagina tissue. Also, MSCs-Exos strongly promoted vascularization in the vaginal reconstruction of rats, which may through the PI3K/AKT signaling pathway.CONCLUSIONThe use of exosome-hydrogel composites improved the epithelial regeneration of vaginal tissue, increased angiogenesis, and promoted smooth muscle tissue regeneration. 3D-printed, lumenal scaffold encapsulating exosomes might be used as a cell-free alternative treatment strategy for vaginal reconstruction.

2024-08-01·Experimental Cell Research

Mesenchymal stem cells-derived exosomes alleviate senescence of retinal pigment epithelial cells by activating PI3K/AKT-Nrf2 signaling pathway in early diabetic retinopathy

Article

作者: Wang, Ying ; Bai, Lifang

Diabetic retinopathy (DR) is a major cause of vision loss and blindness in adults. Cellular senescence was involved in the pathogenesis of early-stage DR and is positively correlated with progression. Thus, our study aimed at exploring the effect and potential mechanism of Mesenchymal stem cells-derived exosomes (MSCs-EXOs) on Retinal Pigment Epithelial (RPE) cells senescence at an early stage of DR in vivo and in vitro. ARPE-19 cells were incubated in high glucose (HG) medium mixed with MSCs-EXOs to observe the changes in cell viability. Senescence-associated β-galactosidase (SA-β-gal) staining, Western blot and qRT-PCR were used to assess the expression of senescence-related genes and antioxidant mediators. Quantitative Real-Time polymerase chain reaction (qRT-PCR), Optical coherence tomography (OCT) Hematoxylin and eosin (HE) staining and Electroretinogram (ERG) were respectively used to verify cellular senescence, the structure and function of the retina. Our findings demonstrated that MSCs-EXOs inhibited HG-induced senescence in ARPE-19 cells. Furthermore, MSCs-EXOs reduced HG-induced cell apoptosis and oxidative stress levels while promoting cell proliferation. Mechanistically, HG suppressed PI3K/AKT phosphorylation as well as nuclear factor erythroid 2-related factor 2 (Nrf2) expression along with its downstream target gene expression in ARPE-19 cells. However, MSCs-EXOs reversed these changes by alleviating cellular senescence while enhancing antioxidant activity. In line with our results in vitro, MSCs-EXOs significantly ameliorated hyperglycemia-induced senescence in DR mice by downregulating mRNA expression of P53, P21, P16, and SASP. Additionally, MSCs-EXOs improved the functional and structural integrity of the retina in DR mice. Our study revealed the protective effect of MSCs-EXOs on cellular senescence, offering new insights for the treatment of DR.

2024-04-01·Bulletin of Experimental Biology and Medicine

Exosomes Derived from Mesenchymal Stem Cells: Therapeutic Opportunities for Spinal Cord Injury

Review

作者: Zhang, C

Spinal cord injury (SCI) is a serious neurological condition comprising primary and secondary injury and causing severe neurological impairments. The effect of the conventional treatment is limited, including supportive therapy and emergency surgery. Exosomes derived from mesenchymal stem cells (MSCs-Exos) were previously reported to exert its potential therapeutic effects on SCI. Compared with mesenchymal stem cells (MSCs) transplantation for SCI, MSC-Exos showed several superiorities. In the present review, we summarized the revealed data of mechanisms underlying MSC-Exos repairing of SCI and discussed the issues of MSC-Exos use. Thus, in this review we summarized the latest studies on MSCs-Exos in the therapy of SCI and discussed whether MSCs-Exos can be applied to SCI and the prospects of transformation application.

100 项与 Mesenchymal stem cell based exosome therapy (Cellular Biomedicine Group) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
成人呼吸窘迫综合征	临床3期	中国	上海交通大学医学院附属瑞金医院	2020-08-16
成人呼吸窘迫综合征	临床3期	中国	上海赛比曼生物科技有限公司	2020-08-16
急性呼吸窘迫综合征	临床2期	中国	AbelZeta Pharma, Inc.	2020-11-30
阿尔茨海默症	临床2期	中国	AbelZeta Pharma, Inc.	2020-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04313647 (CTgov)	临床1期	-	24	1X level of MSCs-Exo (1X Level)	遞範遞窪簾醖糧鹹願繭(糧製簾繭願鏇蓋鑰膚選) = 繭廠構膚繭齋鑰鏇製艱鹽簾衊範觸襯齋膚築膚 (鏇鹽餘築構遞憲鑰願簾, 襯蓋鬱齋膚憲築艱鏇積 ~ 壓鏇壓顧衊淵選廠獵襯) 更多	-	2021-08-04
				2X level of MSCs-Exo (2X Level)	遞範遞窪簾醖糧鹹願繭(糧製簾繭願鏇蓋鑰膚選) = 積願壓衊選顧壓壓齋夢鹽簾衊範觸襯齋膚築膚 (鏇鹽餘築構遞憲鑰願簾, 壓襯鹹窪廠觸觸壓壓憲 ~ 觸襯醖願膚積鏇顧鬱廠) 更多